Gadoxetate

Publication Details

Estimated reading time: 1 minute

CASRN: 135326-11-3

image 135142085 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

There is no published experience with gadoxetate during breastfeeding. Guidelines developed by North American professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a gadolinium-containing contrast medium.[1,2] However, because there is no published experience with gadoxetate during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Copel J, El-Sayed Y, Heine RP, et al. Committee Opinion No. 723: Guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol. 2017;130:e210–e216. [PubMed: 28937575]
2.
American College of Radiology Committee on Drugs and Contrast Media. Administration of contrast media to breast-feeding mothers. In, ACR manual on contrast media. 2022;Version 2022:106-7. https://www​.acr.org/Clinical-Resources​/Contrast-Manual.

Substance Identification

Substance Name

Gadoxetate

CAS Registry Number

135326-11-3

Drug Class

Breast Feeding

Lactation

Milk, Human

Contrast Media

Diagnostic Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.